615 related articles for article (PubMed ID: 2965301)
1. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.
Bichet DG; Razi M; Lonergan M; Arthus MF; Papukna V; Kortas C; Barjon JN
N Engl J Med; 1988 Apr; 318(14):881-7. PubMed ID: 2965301
[TBL] [Abstract][Full Text] [Related]
2. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
3. Two distinct pathophysiological mechanisms in congenital nephrogenic diabetes insipidus.
Moses AM; Miller JL; Levine MA
J Clin Endocrinol Metab; 1988 Jun; 66(6):1259-64. PubMed ID: 3131381
[TBL] [Abstract][Full Text] [Related]
4. Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism.
Bichet DG; Razi M; Arthus MF; Lonergan M; Tittley P; Smiley RK; Rock G; Hirsch DJ
Kidney Int; 1989 Nov; 36(5):859-66. PubMed ID: 2559238
[TBL] [Abstract][Full Text] [Related]
5. Effects of arginine vasopressin and 1-desamino-8-D arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect.
van Lieburg AF; Knoers NV; Monnens LA; Smits P
J Hypertens; 1995 Dec; 13(12 Pt 2):1695-700. PubMed ID: 8903635
[TBL] [Abstract][Full Text] [Related]
6. Normal hemodynamic and coagulation responses to 1-deamino-8-D-arginine vasopressin in a case of lithium-induced nephrogenic diabetes insipidus. Results of treatment by a prostaglandin synthesis inhibitor (indomethacin).
Hober C; Vantyghem MC; Racadot A; Cappoen JP; Lefebvre J
Horm Res; 1992; 37(4-5):190-5. PubMed ID: 1490662
[TBL] [Abstract][Full Text] [Related]
7. Lack of responsiveness to 1-desamino-D arginin vasopressin (desmopressin) in male patients with nephrogenic syndrome of inappropriate antidiuresis: from bench to bedside.
Vandergheynst F; Pradier O; Beukinga I; Kornreich A; Vassart G; Decaux G
Eur J Clin Invest; 2012 Mar; 42(3):254-9. PubMed ID: 21834801
[TBL] [Abstract][Full Text] [Related]
8. Normal response of factor VIII and von Willebrand factor to 1-deamino-8D-arginine vasopressin in nephrogenic diabetes insipidus.
Brenner B; Seligsohn U; Hochberg Z
J Clin Endocrinol Metab; 1988 Jul; 67(1):191-3. PubMed ID: 3132483
[TBL] [Abstract][Full Text] [Related]
9. Characterization of acute hemodynamic effects of antidiuretic agonists in conscious dogs.
Liard JF
J Cardiovasc Pharmacol; 1988 Feb; 11(2):174-80. PubMed ID: 2452311
[TBL] [Abstract][Full Text] [Related]
10. [Congenital nephrogenic diabetes insipidus].
Thibonnier M
Rev Prat; 1994 May; 44(9):1169-72. PubMed ID: 7939338
[TBL] [Abstract][Full Text] [Related]
11. Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta).
Kinter LB; McConnell I; Goodwin BT; Campbell S; Huffman WF; Arthus MF; Lonergan M; Bichet DG
J Pharmacol Exp Ther; 1992 May; 261(2):462-9. PubMed ID: 1578361
[TBL] [Abstract][Full Text] [Related]
12. DDAVP (1-desamino-8-D-arginine vasopressin): an antagonist of the pressor action of endogenous vasopressin?
Derkx FH; Man in 't Veld AJ; Jones R; Reid JL; Schalekamp MA
J Hypertens Suppl; 1983 Dec; 1(2):58-61. PubMed ID: 6400119
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.
Knoers N; Brommer EJ; Willems H; van Oost BA; Monnens LA
Nephron; 1990; 54(4):322-6. PubMed ID: 2109264
[TBL] [Abstract][Full Text] [Related]
14. A variant of nephrogenic diabetes insipidus: V2 receptor abnormality restricted to the kidney.
Knoers N; Monnens LA
Eur J Pediatr; 1991 Mar; 150(5):370-3. PubMed ID: 1828422
[TBL] [Abstract][Full Text] [Related]
15. Normal homeostasis of fibrinolysis in nephrogenic diabetes insipidus in spite of defective V2- receptor-mediated responses of tissue plasminogen activator release.
Brommer EJ; Brink H; Derkx FH; Schalekamp MA; Stibbe J
Eur J Clin Invest; 1990 Feb; 20(1):72-8. PubMed ID: 2138555
[TBL] [Abstract][Full Text] [Related]
16. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.
Bernat A; Hoffmann P; Dumas A; Serradeil-le Gal C; Raufaste D; Herbert JM
J Pharmacol Exp Ther; 1997 Aug; 282(2):597-602. PubMed ID: 9262320
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin receptor mutations causing nephrogenic diabetes insipidus.
Bichet DG; Turner M; Morin D
Proc Assoc Am Physicians; 1998; 110(5):387-94. PubMed ID: 9756088
[TBL] [Abstract][Full Text] [Related]
18. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
19. Platelet vasopressin receptors in patients with congenital nephrogenic diabetes insipidus.
Bichet DG; Arthus MF; Lonergan M
Kidney Int; 1991 Apr; 39(4):693-9. PubMed ID: 1828844
[TBL] [Abstract][Full Text] [Related]
20. [Diabetes insipidus: etiology, diagnosis, and therapy].
Laczi F
Orv Hetil; 2002 Nov; 143(46):2579-85. PubMed ID: 12520852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
